Ionis Pharmaceuticals (IONS) Net Income towards Common Stockholders (2009 - 2026)

Ionis Pharmaceuticals' Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at -$114.6 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 192.79% year-over-year to -$114.6 million; the TTM figure through Jun 2026 stood at -$212.2 million (down 18.94% YoY), while the FY2025 annual figure was -$301.5 million, up 17.2% from the prior year.
• Net Income towards Common Stockholders for Q2 2026 stood at -$114.6 million, down from -$92.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $123.6 million in Q2 2025, with the low at -$147.4 million in Q3 2023.
• The 5-year median for Net Income towards Common Stockholders is -$88.9 million (2023), against an average of -$59.4 million.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders sank 213.58% in 2023, then soared 948.04% in 2025.
• Ionis Pharmaceuticals' Net Income towards Common Stockholders stood at $13.0 million in 2022, then jumped by 612.46% to $92.4 million in 2023, then sank by 115.76% to -$14.6 million in 2024, then jumped by 948.04% to $123.6 million in 2025, then slumped by 192.79% to -$114.6 million in 2026.
• Business Quant data shows IONS's Net Income towards Common Stockholders at -$114.6 million in Q2 2026, -$92.5 million in Q1 2026, and $123.6 million in Q4 2025.